Wilson's disease is a relatively rare inherited disorder of copper accumulation and toxicity, caused by a defect in an enzyme that is part of the pathway of biliary excretion of excess copper. Clinically, patients usually present as older children or young adults with hepatic, neurologic, or psychiatric manifestations, or some combination of these. Wilson's disease is unusual among genetic diseases in that it can be very effectively treated. The prevention of severe permanent damage depends upon early recognition and diagnosis by the physician, followed by appropriate anticopper treatment. Anticopper treatments have evolved considerably since the days when the only drug available was penicillamine. Zinc is now the recommended therapy for long-term management of the disease.
ScheinbergIH, StemliebI.Wilson's disease. In: SmithLHJr.., Ed. Major Problems in Internal Medicine. Philadelphia: W.B. Saunders Company, Vol 23, 1984.
3.
SchilskyML. Wilson disease: Genetic basis of copper toxicity and natural history. Seminars in Liver Disease16: 83–95, 1996.
4.
BullPC, ThomasGR, RommensJM, ForbesJR, CoxDW. The Wilson's disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat Genet5: 327–337, 1993.
5.
TanziRE, PetrukhinK, ChernovI, PellequerJL, WascoW, RossB, RomanoDM, ParanoE, PavoneL, BrzustowiczLM, DevotoM, PeppercornJ, BushAI, SternliebI, PirastuM, GusellaJF, EvgrafovO, PenchaszadehGK, HonigB, EdelmanIS, SoaresMB, ScheinbergIH, GilliamTC. The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nat Genet5: 44–50, 1993.
6.
YamaguchiY, HeinyME, GitlinJD. Isolation and characterization of a human liver cDNA as a candidate gene for Wilson disease. Biochem Biophys Res Commun197: 271–277, 1993.
7.
CoxDW. Review: Molecular approaches to inherited liver disease. Focus on Wilson's disease. J Gastroenterol Hepatol12: S251–S255, 1997.
8.
FrommerDJ. Defective biliary excretion of copper in Wilson's disease. Gut15: 125–129, 1974.
9.
GibbsK, WalsheJM. Biliary excretion of copper in Wilson's disease. Lancet2: 538–539, 1980.
10.
IyengarV, BrewerGJ, DickRD, OwyangC.Studies of cholecysto-kinin-stimulated biliary secretions reveal a high-molecular-weight, copper-binding substance in normal subjects that is absent in patients with Wilsons disease. J Lab Clin Med111: 267–274, 1988.
KayserB.Ueber einen Fall von angeborener grünlicher Verfärbung der kornea. Klin Mbl Augenheilk40: 22–25, 1902.
13.
FleischerB.Zwei weitere Fälle von grünliche Verfärbung der Kornea. Klin Mbl Augenheilk41: 489–491, 1903.
14.
BrewerGJ, HillGM, PrasadAS, CossackZT, RabbaniP.Oral zinc therapy for Wilson's disease. Ann Intern Med99: 314–320, 1983.
15.
HillGM, BrewerGJ, PrasadAS, HydrickCR, HartmannDE. Treatment of Wilson's disease with zinc: I. Oral zinc therapy regimens. Hepatology7: 522–528, 1987.
16.
HillGM, BrewerGJ, JuniJE, PrasadAS, DickRD. Treatment of Wilson's disease with zinc: II. Validation of oral 64copper with copper balance. Am J Med Sci292: 344–349, 1986.
17.
BrewerGJ, HillGM, DickRD, NostrantTT, SamsJS, WellsJJ, PrasadAS. Treatment of Wilson's disease with zinc: III. Prevention of reaccumulation of hepatic copper. J Lab Clin Med109: 526–531, 1987.
18.
BrewerGJ, HillGM, PrasadAS, DickRD. Treatment of Wilson's disease with zinc: IV. Efficacy monitoring using urine and plasma copper. Proc Soc Exp Biol Med7: 446–455, 1987.
19.
Yuzbasiyan-GurkanV, BrewerGJ, AbramsGD, MainB, GiacherioD.Treatment of Wilson's disease with zinc: V. Changes in serum levels of lipase, amylase, and alkaline phosphatase in Wilson's disease patients. J Lab Clin Med114: 520–526, 1989.
20.
BrewerGJ, Yuzbaysian-GurkanV, LeeD-Y, AppelmannH.The treatment of Wilson's disease with zinc: VI. Initial treatment studies. J Lab Clin Med114: 633–638, 1989.
21.
LeeD-Y, BrewerGJ, WangY.The treatment of Wilson's disease with zinc: VII. Protection of the liver from copper toxicity by zinc-induced metallothionein in a rat model. J Lab Clin Med114: 639–645, 1989.
22.
BrewerGJ, Yuzbasiyan-GurkanV, DickR.Zinc therapy of Wilson's disease: VIII. Dose-response studies. Trace Elem Exp Med3: 227–234, 1990.
23.
BrewerGJ, Yuzbasiyan-GurkanV, JohnsonV.The treatment of Wilson's disease with zinc: DC. Response of serum lipids. J Lab Clin Med118: 466–470, 1991.
24.
Yuzbasiyan-GurkanV, GriderA, NostrantT, CousinsRJ, BrewerGJ. The treatment of Wilson's disease with zinc: X. Intestinal metallothionein induction. J Lab Clin Med120: 380–386, 1992.
25.
BrewerGJ, Yuzbasiyan-GurkanV, JohnsonV, DickRD, WangY.Treatment of Wilson's disease with zinc: XI. Interaction with other anticopper agents. J Am Coll Nutr12: 26–30, 1993.
26.
BrewerGJ, Yuzbasiyan-GurkanV, JohnsonV, DickRD, WangY.Treatment of Wilson's disease with zinc: XII. Dose regimen requirements. Am J Med Sci305: 199–202, 1993.
27.
BrewerGJ, DickRD, Yuzbasiyan-GurkanV, JohnsonV, WangY.Treatment of Wilson's disease with zinc XUJ. Therapy with zinc in presymptomatic patients from the time of diagnosis. J Lab Clin Med123: 849–858, 1994.
28.
BrewerGJ, JohnsonV, KaplanJ.Treatment of Wilson's disease with zinc: XIV. Studies of the effect of zinc on lymphocyte function. J Lab Clin Med129: 649–652, 1997.
29.
BrewerGJ, DickRD, JohnsonV, BrunbergJA, KluinKJ, FinkJK. Treatment of Wilson's disease with zinc: XV. Long-term follow-up studies. J Lab Clin Med132: 264–278, 1998.
30.
BrewerGJ, BrewerLF, PrasadAS. Suppression of irreversibly sickled erythrocytes by zinc therapy in sickle cell anemia. J Lab Clin Med90: 549–554, 1977.
31.
BrewerGJ, SchoomakerEB, LeichtmanDA, KrucklebergWC, BrewerLF, MyersN.The uses of pharmacologic doses of zinc in the treatment of sickle cell anemia. In: BrewerGJ, PrasadAS, Eds. Zinc Metabolism: Current Aspects in Health and Disease. New York: Allan R. Liss, Inc., pp 241–258, 1977.
32.
PrasadAS, BrewerGJ, SchoomakerEB, RabbiniP.Hypocupremia induced by zinc therapy in adults. JAMA240: 2166–2168, 1978.
33.
SchouwinkG.De hepatocecerebrale degeneratie, met een onderzoek naar de zonkstrofwisseling. MD thesis (with a summary in English, French, and German). University of Amsterdam, 1961.
34.
HoogenraadTU, KoevoetR, De Ruyter KorverEGWM.Oral zinc sulfate as long-term treatment in Wilson's disease (hepatolenticular degeneration). Eur Neurol18: 205–211, 1979.
35.
HoogenraadTU, Van den HamerCIA, KoevoetR, De Ruyter KorverEGWM.Oral zinc in Wilson's disease. Lancet2: 1262–1263, 1978.
36.
HoogenraadTU, Van HattumJ, Van den HamerCJA.Management of Wilson's disease with zinc sulfate: Experience in a series of 27 patients. J Neurol Sci77: 137–146, 1987.
37.
HallAC, YoungBW. Bremner I. Intestinal metallothionein and the mutual antagonism between copper and zinc in the rat. J Inorg Biochem11: 57–66, 1979.
38.
MenardMP, McCormickCC, CousinsRJ. Regulation of intestinal metallothionein biosynthesis in rats by dietary zinc. J Nutr111: 1351–1361, 1981.
39.
OestreicherP, CousinsRJ. Copper and zinc absorption in the rat: Mechanism of mutual antagonism. J Nutr115: 159–166, 1985.
40.
WalsheJM. Treatment of Wilson's disease with trientine (triethylene tetramine) dichloride. Lancet1: 643–647, 1982.
41.
KeenCL, LonnerdalB, HurleyLS. Teratogenic effect of copper deficiency and excess. In: SorensonJRJ, Ed. Inflammatory diseases and copper. Clifton. NJ: Humana Press, pp 109–121, 1982.
42.
WalsheJM. Penicillamine: A new oral therapy for Wilson's disease. Am J Med21: 487–495, 1956.
43.
BrewerGJ, TerryCA, AisenAM, HillGM. Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy. Arch Neurol44: 490–493, 1987.
44.
NimniME, BavettaLA. Collagen defect induced by penicillamine. Science150: 905–907, 1965.
45.
RonchettiIP, FomieriC, ContriMB, QuaglinoDJr.Effect of DL-penicillamine on the aorta of growing chickens. Am J Pathol124: 436–447, 1986.
46.
MjolnerodOK, DommerudSA, RasmussenK, GjeruldsenST. Congenital connective tissue defect probably due to d-penicillamine treatment in pregnancy. Lancet1: 673–675, 1971.
47.
SolomonL, AbramsG, DinnerM, BermanL.Neonatal abnormalities associated with d-penicillamine treatment during pregnancy. N Engl J Med296: 54–55, 1977.
48.
MasonJ.The biochemical pathogenesis of molybdenum-induced copper deficiency syndromes in ruminants: Towards the final chapter. Ir Vet J43: 18–21, 1990.
49.
MillsCF, El-GalladTT, BremnerI.Effects of molybdate, sulfide, and tetrathiomolybdate on copper metabolism in rats. J Inorg Biochem14: 189–207, 1981.
50.
BremnerI, MillsCF, YoungBW. Copper metabolism in rats given di-or trithiomolybdates. J Inorg Biochem16: 109–119, 1982.
51.
MillsCT, El-GalladTT, BremnerI, WehamG.Copper and molybdenum absorption by rats given ammonium tetrathiomolybdate. J Inorg Biochem14: 163–175, 1981.
52.
GooneratneSR, HowellJM, GawthomeJM. An investigation of the effects of intravenous administration of thiomolybdate on copper metabolism in chronic Cu-poisoned sheep. Br J Nutr46: 469–480, 1981.
53.
BrewerGJ, DickRD, Yuzbasiyan-GurkinV, TanakowR, YoungAB, KluinKJ. Initial therapy of patients with Wilson's disease with tetrathiomolybdate. Arch Neurol48: 42–47, 1991.
54.
BrewerGJ, DickRD, JohnsonV, WangY, Yuzbasiyan-GurkinV, KluinKJ, FinkJK, AisenA.Treatment of Wilson's disease with ammonium tetrathiomolybdate: I. Initial therapy in 17 neurologically affected patients. Arch Neurol51: 545–554, 1994.
55.
BrewerGJ, JohnsonV, DickRD, WangY, KluinKJ, FinkJK, BrunbergJA. Treatment of Wilson Disease with ammonium tetrathiomolybdate: II. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapy. Arch Neurol53: 1017–1025, 1996.
56.
HarperPI, WalsheJM. Reversible pancytopenia secondary to treatment with tetrathiomolybdate. Br J Haematol64: 851–853, 1986.
57.
NazerH, EdeRJ, MowatAP, WilliamsR.Wilson's disease: Clinical presentation and use of prognostic index. Gut27: 1377–1381, 1986.
